Participants and family members of participants currently enrolled under IRB #354-06 and #355-06 who have been identified as members of a family with at least one blood related relative with pancreas cancer, and there is a known mutation carrier of CDKN2A. Some of the family members may have previously enrolled in IRB protocol #354-06 or #355-06; others may not have ever participated in research.